BioCentury | Apr 17, 2021
Deals

As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region

An improving environment for translational science in Germany has prompted Evotec to launch its latest incubator in the country. This week Evotec SE (Xetra:EVT) announced that it has partnered with Bristol Myers Squibb Co. (NYSE:BMY)...
BioCentury | Apr 16, 2021
Politics, Policy & Law

Pandemic pain: how COVID-19 has devastated patient groups

COVID-19 has devastated patient groups that prior to spring 2020 relied heavily on in-person events to raise funds, build communities and promote awareness. The cutbacks have set back scientific research, harmed vulnerable patients and undermined...
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 9, 2021
Politics, Policy & Law

BIO 3.0: Reinventing the trade association

BIO is rebooting itself, creating what could be called BIO 3.0, the third reimagination of the organization following the paths charted by Carl Feldbaum, who led it from 1993 to 2005, and Jim Greenwood,...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

Cross-border firm Remiges Ventures will deploy its $95 million second fund to launch start-ups out of Japanese academia and invest in syndicated series A rounds, with a newly launched incubator to help...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is developing ADC Therapeutics’ loncastuximab tesirine, a pyrrolobenzodiazepine (PBD) dimer-linked...
BioCentury | Mar 30, 2021
Deals

Deerfield’s growing umbrella: Data Byte

Since 2017, Deerfield Management has committed $1.2 billion across 14 umbrella research agreements to accelerate the creation of newcos out of academic discoveries. The partnerships are structured around a joint steering committee comprising members from...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
Items per page:
1 - 10 of 1056
BioCentury | Apr 17, 2021
Deals

As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region

An improving environment for translational science in Germany has prompted Evotec to launch its latest incubator in the country. This week Evotec SE (Xetra:EVT) announced that it has partnered with Bristol Myers Squibb Co. (NYSE:BMY)...
BioCentury | Apr 16, 2021
Politics, Policy & Law

Pandemic pain: how COVID-19 has devastated patient groups

COVID-19 has devastated patient groups that prior to spring 2020 relied heavily on in-person events to raise funds, build communities and promote awareness. The cutbacks have set back scientific research, harmed vulnerable patients and undermined...
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 9, 2021
Politics, Policy & Law

BIO 3.0: Reinventing the trade association

BIO is rebooting itself, creating what could be called BIO 3.0, the third reimagination of the organization following the paths charted by Carl Feldbaum, who led it from 1993 to 2005, and Jim Greenwood,...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

Cross-border firm Remiges Ventures will deploy its $95 million second fund to launch start-ups out of Japanese academia and invest in syndicated series A rounds, with a newly launched incubator to help...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is developing ADC Therapeutics’ loncastuximab tesirine, a pyrrolobenzodiazepine (PBD) dimer-linked...
BioCentury | Mar 30, 2021
Deals

Deerfield’s growing umbrella: Data Byte

Since 2017, Deerfield Management has committed $1.2 billion across 14 umbrella research agreements to accelerate the creation of newcos out of academic discoveries. The partnerships are structured around a joint steering committee comprising members from...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
Items per page:
1 - 10 of 1056